Literature DB >> 30171802

Noninvasive quantification of intrarenal allograft C4d deposition with targeted ultrasound imaging.

Tao Liao1, Yannan Zhang1, Jie Ren2, Haofeng Zheng1, Hongjun Zhang2, Xiujie Li3, Xiaonan Liu1, Tinghui Yin2, Qiquan Sun1.   

Abstract

Antibody-mediated rejection (AMR) has emerged as a major cause of renal allograft dysfunction. C4d, a specific marker for AMR diagnosis, was strongly recommended for routine surveillance; however, currently, C4d detection is dependent upon tissue biopsy, which is invasive and provides only local semi-quantitative data. Targeted ultrasound imaging has been used extensively for noninvasive and real-time molecular detection with advantages of high specificity and sensitivity. In this study, we designed C4d-targeted microbubbles (MBC4d ) using a streptavidin-biotin conjugated method and detected C4d deposition in vivo in a rat model of AMR by enhanced ultrasound imaging. This noninvasive procedure allowed successful acquisition of the first qualitative image of C4d deposition in a wide renal allograft section, which reflected real-time C4d distribution in grafts. Moreover, we introduced normal intensity difference for quantitative analysis, which exhibited a nearly linear correlation with the grade of C4d deposition according to pathologic analysis. In addition, this approach showed no influence on survival rates and pathologic features in the microbubble injection groups, thereby demonstrating its safety. These findings demonstrated a simple, noninvasive, quantitative, and safe evaluation method for C4d, with the utility of this approach potentially preventing patients from having to undergo an invasive biopsy.
© 2018 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  alloantibody; animal models; basic (laboratory) research/science; biomarker; biopsy; kidney transplantation/nephrology; pathology/histopathology; rejection: antibody-mediated (ABMR); translational research/science

Mesh:

Substances:

Year:  2018        PMID: 30171802     DOI: 10.1111/ajt.15105

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  7 in total

Review 1.  Complement and the Kidney: An Overview.

Authors:  Joshua M Thurman
Journal:  Adv Chronic Kidney Dis       Date:  2020-03       Impact factor: 3.620

Review 2.  Renal Allograft Rejection: Noninvasive Ultrasound- and MRI-Based Diagnostics.

Authors:  Ulrich Jehn; Katharina Schuette-Nuetgen; Dominik Kentrup; Verena Hoerr; Stefan Reuter
Journal:  Contrast Media Mol Imaging       Date:  2019-04-10       Impact factor: 3.161

3.  Prediction of renal allograft chronic rejection using a model based on contrast-enhanced ultrasonography.

Authors:  Cheng Yang; Shengdi Wu; Ping Yang; Guoguo Shang; Ruochen Qi; Ming Xu; Ruiming Rong; Tongyu Zhu; Wanyuan He
Journal:  Microcirculation       Date:  2019-04-14       Impact factor: 2.628

4.  Depletion of Toll-Like Receptor-9 Attenuates Renal Tubulointerstitial Fibrosis After Ischemia-Reperfusion Injury.

Authors:  Haofeng Zheng; Yannan Zhang; Lei Li; Rui Zhang; Zihuan Luo; Zhe Yang; Yongrong Ye; Jiannan He; Qiquan Sun
Journal:  Front Cell Dev Biol       Date:  2021-02-12

5.  Blockade of IL-6/IL-6R Signaling Attenuates Acute Antibody-Mediated Rejection in a Mouse Cardiac Transplantation Model.

Authors:  Maolin Ma; Qipeng Sun; Xiujie Li; Gengguo Deng; Yannan Zhang; Zhe Yang; Fei Han; Zhengyu Huang; Youqiang Fang; Tao Liao; Qiquan Sun
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561

6.  Ex vivo anchored PD-L1 functionally prevent in vivo renal allograft rejection.

Authors:  Zihuan Luo; Tao Liao; Yannan Zhang; Haofeng Zheng; Qipeng Sun; Fei Han; Maolin Ma; Yongrong Ye; Qiquan Sun
Journal:  Bioeng Transl Med       Date:  2022-04-06

7.  Hydroxychloroquine Inhibits Macrophage Activation and Attenuates Renal Fibrosis After Ischemia-Reperfusion Injury.

Authors:  Haofeng Zheng; Yannan Zhang; Jiannan He; Zhe Yang; Rui Zhang; Lei Li; Zihuan Luo; Yongrong Ye; Qiquan Sun
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.